Victory in California! Drug Price Transparency Bill Becomes LawOctober 10, 2017  

After a long, tough fight with drug companies, consumers in California can rejoice. Yesterday, California Governor Jerry Brown signed SB 17, a drug price transparency bill, into law. In his statement, Brown said there is “real evil when so many people are suffering so much from rising drug prices…The essence of this bill is pretty simple. Californians have a right to know why their medical costs are out of control, especially when the pharmaceutical profits are soaring…This measure is a step at bringing transparency, truth, exposure to a very important part of our lives — that is the cost of prescription drugs.” The new law will go into effect on January 1st, 2018. The law’s goal is make drug prices for both private and public health plans more transparent in California. It would do so by requiring drug companies to give health insurers and government health plans at least sixty days’ warning before prescription drug hikes that would exceed 16% over a two-year period. Drug companies will also have to provide reasons behind the price increases. Big Pharma strongly opposed the bill and spend millions of dollars on lobbyists and advertising to defeat it, partly because of a fear that it will be the first step toward drug price controls, and partly because they don’t want consumers to have accurate information. But all their efforts were in vain, and consumers will be much better off. Drug prices have been skyrocketing over the past decade, and policymakers want to take action to reduce them. One of the major problems has been a great lack of information on drug prices, what contributes to their increase, and who is responsible for the harm to consumers. The passage of SB 17 shows that transparency bills are not doomed to defeat, it will give officials and consumers helpful tools for further reforms, and it will shine a spotlight on egregious abuses by Big Pharma.  Congress Bans Gag-Clauses on PharmacistsSeptember 27, 2018The Promise of BiosimilarsDecember 11, 2017United States-Mexico-Canada Agreement (USMCA)October 5, 2018Consumer Groups and Unions Submit Letter in Support of PBM Bill Lowering Drug PricesDecember 17, 2019House of Representatives Passes Bill Allowing Medicare to Negotiate For Lower Drug PricesDecember 13, 2019Panel Examines Patent Abuse and How It Contributes to Rising Drug PricesDecember 10, 2019Massachusetts Senate Passes Bill to Regulate PBMsDecember 4, 2019FTC Approves Bristol-Myers Squibb and Celgene Merger, Two FTC Commissioners Issue Strong DissentsNovember 18, 2019Legal Challenges to State PBM LawsNovember 17, 2019American College of Physicians Calls for Transparency From Pharmacy Benefit ManagersNovember 14, 2019New Report Finds That Employers Are Increasingly Making Employees Pay Higher Prices for DrugsNovember 14, 2019At Axios Forum, Secretaries and Legislators Push for Measures to Lower Drug PricesNovember 13, 2019Department of Health and Human Services Sues Gilead for Patent Infringement and Ripping Off TaxpayersNovember 9, 2019December 2019 (4)November 2019 (7)October 2019 (6)September 2019 (8)August 2019 (5)July 2019 (10)June 2019 (8)May 2019 (10)April 2019 (10)March 2019 (6)February 2019 (12)January 2019 (11)December 2018 (5)November 2018 (6)October 2018 (8)September 2018 (4)July 2018 (1)January 2018 (1)December 2017 (4)November 2017 (6)October 2017 (8)September 2017 (13)August 2017 (10)July 2017 (8)June 2017 (14)May 2017 (11)April 2017 (4)March 2017 (10)February 2017 (4)January 2017 (3)December 2016 (17)November 2016 (10)October 2016 (4)September 2016 (2)August 2016 (8)July 2016 (12)June 2016 (11)May 2016 (10)April 2016 (6)March 2016 (9)February 2016 (4)January 2016 (5)December 2015 (3)October 2015 (4)ConsumersDOJInsurance CommissionersLuxotticaattorney generalhealth insurancehealth insurance competitionhealth insurance mergershow do I file a complaint?how do insurance mergers workmerger processmerger reviewmergerssize of Aetna Humana mergersize of Anthem and Cigna mergerstate impacttimeline for mergers